Inhaled dry powder mannitol: A solution for cystic fibrosis

American Journal of Respiratory and Critical Care Medicine

Volumn 185, Issue 6, 2012, Pages 596-598

  Trapnell, Bruce C ^a  

^a UNIVERSITY OF CINCINNATI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DORNASE ALFA; MANNITOL; RECOMBINANT DEOXYRIBONUCLEASE; SODIUM CHLORIDE; TRANSMEMBRANE CONDUCTANCE REGULATOR; UNCLASSIFIED DRUG;

BRONCHOSPASM; COUGHING; CYSTIC FIBROSIS; DISEASE EXACERBATION; DRY POWDER; EDITORIAL; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; GENE MUTATION; HEMOPTYSIS; HUMAN; LOW DRUG DOSE; LUNG FUNCTION; MUCOCILIARY CLEARANCE; PATHOGENESIS; POWDER INHALER; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; SORE THROAT; TREATMENT DURATION;

CYSTIC FIBROSIS; FEMALE; HUMANS; MALE; MANNITOL; MUCOCILIARY CLEARANCE;

EID: 84858229591     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201112-2205ED     Document Type: Editorial

References (13)

1. Kerem B, Rommens JM, Buchanan JA, Markiewicz D, Cox TK, Chakravarti A, Buchwald M, Tsui LC. Identification of the cystic fibrosis gene: genetic analysis. Science 1989;245:1073-1080. (Pubitemid 19231815)
2. Matsui H, Grubb BR, Tarran R, Randell SH, Gatzy JT, Davis CW, Boucher RC. Evidence for periciliary liquid layer depletion, not abnormal ion composition, in the pathogenesis of cystic fibrosis airways disease. Cell 1998;95:1005-1015. (Pubitemid 29019052)
3. Puchelle E, Bajolet O, Abely M. Airway mucus in cystic fibrosis. Paediatr Respir Rev 2002;3:115-119. (Pubitemid 35331504)
4. Donaldson SH, Bennett WD, Zeman KL, Knowles MR, Tarran R, Boucher RC. Mucus clearance and lung function in cystic fibrosis with hypertonic saline. N Engl J Med 2006;354:241-250. (Pubitemid 43113029)
5. Elkins MR, Robinson M, Rose BR, Harbour C, Moriarty CP, Marks GB, Belousova EG, Xuan W, Bye PT. A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. N Engl J Med 2006;354:229-240. (Pubitemid 43113028)
6. Daviskas E, Anderson SD, Brannan JD, Chan HK, Eberl S, Bautovich G. Inhalation of dry-powder mannitol increases mucociliary clearance. Eur Respir J 1997;10:2449-2454. (Pubitemid 28048614)
7. Jaques A, Daviskas E, Turton JA, McKay K, Cooper P, Stirling RG, Robertson CF, Bye PT, Lesouef PN, Shadbolt B, et al. Inhaled mannitol improves lung function in cystic fibrosis. Chest 2008;133:1388-1396. (Pubitemid 351892995)
8. Teper A, Jaques A, Charlton B. Inhaled mannitol in patients with cystic fibrosis: a randomised open-label dose response trial. J Cystic Fibrosis 2011;10:1-8.
9. Bilton D, Robinson P, Cooper P, Gallagher CG, Kolbe J, Fox H, Jaques A, Charlton B. Inhaled dry powder mannitol in cystic fibrosis: an efficacy and safety study. Eur Respir J 2011;38:1071-1080.
10. Aitken M, Bellon G, De Boeck K, Flume PA, Fox HG, Geller DE, Haarman EG, Hebetreit HU, Lapey A, Manjula Schou I, et al. Long-term inhaled dry powder mannitol in cystic fibrosis: an international randomized study. Am J Respir Crit Care Med 2012;185:645-652.
11. Fuchs HJ, Borowitz DS, Christiansen DH, Morris EM, Nash ML, Ramsey BW, Rosenstein BJ, Smith AL, Wohl ME. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis: the Pulmozyme Study Group. N Engl J Med 1994;331:637-642. (Pubitemid 24276863)
12. Mayer-Hamblett N, Ramsey BW, Kronmal RA. Advancing outcome measures for the new era of drug development in cystic fibrosis. Proc Am Thorac Soc 2007;4:370-377. (Pubitemid 47330874)
13. Ramsey BW, Davies J, McElvaney NG, Tullis E, Bell SC, Drevinek P, Griese M, McKone EF, Wainwright CE, Konstan MW, et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med 2011;365:1663-1672.